2012
DOI: 10.1038/aps.2012.44
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Aim: To evaluate the single-and multiple-dose pharmacokinetics of vincristine sulfate liposomes (VSLI) in patients with advanced solid tumors. Methods: In single-dose pharmacokinetic study, 16 patients were administered VSLI (1.5, 2.0, or 2.3 mg·m -2 ) through intravenous infusion. Another 6 patients receiving vincristine sulfate (VCR, 2.0 mg) were taken as the control. In multiple-dose pharmacokinetic study, 12 patients were administered VSLI (1.5 or 1.8 mg·m -2 ) through intravenous infusion weekly for 4 con… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
26
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 33 publications
(28 citation statements)
references
References 16 publications
2
26
0
Order By: Relevance
“…Clinical Studies of Marqibo. As observed in animal models, Marqibo administered to humans demonstrated a similar improvement over standard vincristine (Thomas et al, 2009;Yan et al, 2012;O'Brien et al, 2013). Indeed, higher doses of Marqibo were able to be administered to patients compared with standard vincristine (Hagemeister et al, 2013;O'Brien et al, 2013).…”
Section: Marqibomentioning
confidence: 55%
See 1 more Smart Citation
“…Clinical Studies of Marqibo. As observed in animal models, Marqibo administered to humans demonstrated a similar improvement over standard vincristine (Thomas et al, 2009;Yan et al, 2012;O'Brien et al, 2013). Indeed, higher doses of Marqibo were able to be administered to patients compared with standard vincristine (Hagemeister et al, 2013;O'Brien et al, 2013).…”
Section: Marqibomentioning
confidence: 55%
“…A single dose injection of 2.0 mg/m 2 Marqibo into patients with solid tumors demonstrated an increase in the plasma AUC and a reduction in the clearance rate of encapsulated vincristine compared with patients treated with a single 2.0 mg/m 2 dose of standard vincristine (Yan et al, 2012). However, the concentration-dependent 756 efficacy of Marqibo was not significantly different in this study when the Marqibo dose was changed to 1.5 or 2.3 mg/m 2 .…”
Section: Marqibomentioning
confidence: 94%
“…Patients treated with a single 2.0 mg/m 2 dose of the encapsulated VSLI formulation exhibited increased plasma AUC and decreased clearance rates compared with those treated with 2.0 mg/m 2 of conventional VCR. 34 Interestingly, variation of VSLI dose (1.5, 2.0, or 2.3 mg/m 2 ) or number of doses (1.5 or 1.8 mg/m 2 weekly for four cycles) did not significantly alter the PK of VSLI in these patients. 34 However, it should be noted that the patients in this study were Chinese and exhibited lower AUC and Cmax at a VSLI dose of 2.0 mg/m 2 compared with previous studies, 40,41 suggesting that pharmacogenomics may contribute to the PK of VSLI.…”
Section: Liposomal Vincristine Sulfate Injectionmentioning
confidence: 78%
“…32 Data from pharmacokinetic (PK) studies revealed that clearance of liposome-encapsulated VCR was slower than that for free VCR and was thought to contribute to the higher plasma concentrations observed over a longer time period for liposomal VCR. 34,35 For example, a preclinical model comparing conventional, aqueous VCR, DSPC/cholesterol, and sphingomyelin/cholesterol liposomal formulations showed that the encapsulated drug exhibited a significantly larger area under the concentration curve (AUC) (measure of bioavailability), a longer mean plasma residence time, and a lower volume of distribution. 35 Importantly, the progressive in vivo accumulation of VCR in tissues, based on maximum concentration (Cmax), demonstrates a preference for mononuclear phagocyte system tissues such as spleen, liver, lymph nodes, and bone marrow, 36 correlating to those tissues most affected by leukemic burden.…”
Section: Liposomal Vincristine Sulfate Injectionmentioning
confidence: 99%
“…Vincristine and vinblastine are known, highly valuable terpenoid indole alkaloids (TIAs) from over 130 alkaloids, which were found in C. roseus. Dimeric TIA VCR has been widely used as an antitumor agent since the 1960s [1][2][3][4][5][6][7][8]. C. roseus has been used in traditional medicine in tropical and subtropical countries for the treatment of diabetes, hypertension, bleeding, scurvy, toothaches, and others from ancient time.…”
Section: Introductionmentioning
confidence: 99%